The treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) is based on targeting the prostate-specific membrane antigen (PSMA), which is a transmembrane glycoprotein that is overexpressed in malignant prostate cancer cells [2]. This evidence concerns the gene FOLH1 and Familial prostate cancer.